Roche. Q results. Basel, 26 April 2018

Transcription

1

2 Roche Q results Basel, 26 April 2018

3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected. 3

4 Group Severin Schwan Chief Executive Officer

5 Q1 2018: Strong sales growth in both divisions Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division Diagnostics Division Roche Group CER=Constant Exchange Rates 5

6 Q1 2018: Sales growth for the seventh consecutive year 10% 8% 6% 6% 6% 6% 8% 7% 5% 6% 7% 6% 6% 6% 6% 6% 4% 4% 4% 4% 5% 5% 4% 4% 4% 5% 2% 2% 3% 3% 0% Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 All growth rates at Constant Exchange Rates (CER) 6

7 Q1 2018: Strong sales growth in US and International CHFbn % +8% % -5% +15% +9% -1% 0% -8% +5% -7% 0% Japan International Europe US Diagnostics Pharma All growth rates at Constant Exchange Rates (CER) 7

8 Roche significantly advancing patient care, BTD s reflecting the quality of our research Phase duration (years) No = 7.5 Fast track = 5.8 Accelerated review = 3.8 Breakthrough therapy = 3.6 8

9 2018: New products with annualized sales of >CHF 8bn* ~80% of growth driven by new products * Venclexta sales are booked by partner AbbVie. 9

10 Replace and extend the business Through continuously improving standard of care Replace existing businesses Entering new franchises Achievements Q MabThera Herceptin Avastin Lucentis Tamiflu Gazyva, Venclexta, polatuzumab vedotin, Sub Cut Perjeta, Kadcyla, Sub Cut Tecentriq, entrectinib VA2, port delivery baloxavir (Cap Endo) MS: Ocrevus Hemophilia: Hemlibra CNS: SMA, Autism, Huntington s Perjeta: Gazyva: Hemlibra: Tecentriq: Venclexta: baloxavir: Launched in ebc in US Launched in FL in US/EU Launched in inh. patients in US/EU; BTD in non-inh. IMpower150 with OS benefit Launched in 17p del; Filed in CLL R/R Filing initiated in US entrectinib: Acquisition of Ignyta completed VA2: Strong Ph II data in DME VA2=anti-VEGF/anti-angiopoietin-2 bispecific antibody; MS=multiple sclerosis; SMA=spinal muscular atrophy; ebc=early breast cancer; FL=follicular lymphoma; BTD=Breakthrough Therapy Designation; CLL R/R=relapsed/refractory (R/R) chronic lymphocytic leukemia; DME=diabetic macular edema 10

11 Record number of NMEs at pivotal stage Q1 entrants: Anti-VEGF/Ang2 bimab, entrectinib, baloxavir marboxil Oncology Ophthalmology Neuroscience Immunology Infectious Disease NME=new molecular entities; For details on the indications and line extensions please consult the pipeline appendix. Cap Endonuclease inhibitor (baloxavir marboxil) 11

12 2018 outlook raised From stable to low single digit to low single digit Group sales growth 1 Low-single digit Core EPS growth 1 Broadly in line with sales, excl. US tax reform benefit High-single digit, incl. US tax reform benefit Dividend outlook Further increase dividend in Swiss francs 1 Sales growth at Constant Exchange Rates (CER) 12

13 Pharmaceuticals Division Daniel O Day CEO Roche Pharmaceuticals 13

14 Q performance Innovation Outlook 14

15 Q1 2018: Pharma sales Accelerated growth in US due to new products Change in % CHFm CHFm CHF CER Pharmaceuticals Division 10,672 10, United States 5,516 5, Europe 2,287 2, Japan International 2,018 1, CER=Constant Exchange Rates 15

16 Q1 2018: New products with strong momentum, out growing biosimilar onset Absolute values and growth rates at Constant Exchange Rates (CER) 16

17 Q1 2018: Oncology sales stable YoY CER growth Perjeta HER2 Herceptin +6% Perjeta: Strong growth in all regions; US momentum due to early APHINITY approval Kadcyla: Growth driven by International Avastin Hematology MabThera/Rituxan (Oncology) Gazyva/Gazyvaro -2% -7% Kadcyla EU: Decline largely due to price cut in France US/EU: 1L lung cancer shares stable after CIT entry US/EU: Good initial uptake of Gazyva in 1L FL in the early launch countries Tarceva Tecentriq Alecensa Cotellic + Zelboraf CHFbn -32% +29% +81% Cotellic -6% Increased competition EU: Launch in lung (2/3L) and bladder (2L and 1L cisplatin ineligible) ongoing US: 2L lung cancer and 1L cisplatin ineligible bladder shares stable US: 1L new patient market share of >50% achieved following 1L approval in Q4 EU: Strong 1L launch in key markets EU: Increasing competition from CIT Q Oncology sales: CHF 6.4bn (CER growth 0%); All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy; FL=follicular lymphoma 17

18 Her2 franchise: Growth driven by Perjeta CHFm YoY CER growth 3,000 2,500 2,000 1, % +9% +6% +6% Her2 franchise Q Perjeta US (+18%): Accelerated growth driven by ebc following approval in the adjuvant setting (APHINITY) Perjeta in ebc on NCCN, St. Gallen, and AGO (Germany) guidelines 1, Q1 15 Q1 16 Q1 17 Q1 18 Herceptin Perjeta Kadcyla Outlook 2018 US: Continued Perjeta uptake in ebc EU: Approval in adjuvant BC (APHINITY) EU: Market entry of Herceptin biosimilars CER=Constant Exchange Rates; ebc=early breast cancer; NCCN=National Comprehensive Cancer Network; AGO=Arbeitsgemeinschaft Gynäkologische Onkologie 18

19 Hematology: Entering the rejuvenation phase CHFm YoY CER growth Hematology Q ,000 CD20 franchise 1,500 +5% +3% +4% -7% MabThera (onc) US (+2%): Stable volumes in all indications MabThera (onc) EU (-43%): Biosimilar roll-out ongoing Gazyva (+27%): Growth driven by 1L FL early launches Venclexta* 1,000 Venclexta sales reached USD 59m (+179%) with ~40% patient share reached in R/R CLL with 17p deletion Q1 15 Q1 16 Q1 17 Q1 18 MabThera/Rituxan (Onc) Gazyva/Gazyvaro Outlook 2018 US: first biosimilar entry in H2 expected US/EU approval Venclexta + Rituxan in R/R CLL (MURANO) Ph II data for Polatuzumab vedotin + BR in R/R DLBCL to be shared with health authorities CER=Constant Exchange Rates; FL=follicular lymphoma; CLL=chronic lymphoid leukemia; BR=bendamustine+Rituxan; DLBCL=diffuse large B-cell lymphoma; * Venclexta sales are booked by partner AbbVie. 19

20 Alecensa: US market leadership in 1L ALK+ NSCLC achieved CHFm % YoY CER growth +81% Alecensa Q US: New patient share of >50% in first quarter of launch Launch supported by FMI`s NGS-based companion diagnostic (FoundationOne CDx) and approval of the Ventana companion diagnostic EU: Strong launch in key markets % Q1 15 Q1 16 Q1 17 Q1 18 US Europe International Japan Outlook 2018 Continued 1L momentum Updated mpfs data from Ph III study (ALEX) comparing Alecensa vs crizotinib to be presented at ASCO Ph III adjuvant study (ALINA) initiated CER=Constant Exchange Rates; FMI=Foundation Medicine; NGS=next generation sequencing 20

21 Immunology: Annualized sales of around CHF 8bn CHFm 2,000 1,600 1, % +16% YoY CER growth +4% +11% Immunology Q Esbriet (+13%) Penetration in mild to moderate patient segment increasing Xolair (+7%) Growth driven by pediatric asthma, allergic asthma and CIU 800 Actemra (+13%) 400 Launch in giant cell arteritis ongoing Auto-injector approved in the EU and Australia 0 Q1 15 Q1 16 Q1 17 Q1 18 MabThera/Rituxan (RA) Actemra IV Actemra SC Xolair CellCept Pulmozyme Esbriet Other Outlook 2018 Strong growth expected with the exception of MabThera CER=Constant Exchange Rates; CIU=chronic idiopathic urticaria 21

22 Ocrevus: Strong EU launch; ~7% US market share after 3 quarters CHFm Q2 17 Q3 17 Q4 17 Q1 18 US Europe International Ocrevus Q Strong launches in EU and International US growing due to increasing number of returning patients and new patients RMS: 30% treatment naive/previously discontinued vs. 70% switches from all other approved medications Outlook 2018 Continued launches in EU and International Further increasing US market share with earlier use RMS=relapsing forms of multiple sclerosis 22

23 2018: New products with annualized sales of >CHF 8bn* ~80% of growth driven by new products * Venclexta sales are booked by partner AbbVie. 23

24 Q performance Innovation Outlook 24

25 CIT 1L lung cancer program reading out in H IMpower133 1 (Tecentriq+cb+etoposide) PFS/OS IMpower150 (Tecentriq+cb/pac+/-Avastin) PFS/OS (H1 2018) (PFS) (OS) IMpower131 (Tecentriq+cb+pac/nab-pac) PFS/OS (PFS) With liver metastases IMpower130 (Tecentriq+cb+nab-pac) PFS/OS IMpower132 (Tecentriq+cp/cb+pem) PFS/OS = Roche with potential first chemo combo March 26: IMpower150 met co-primary OS endpoint at interim analysis March 20: IMpower131 met co-primary PFS endpoint Source: Datamonitor; incidence rates 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); Note: Outcome studies are event driven, timelines may change; 1 IMpower133 in extensive stage SCLC; CIT=cancer immunotherapy; cb=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); cp=cisplatin; pem=pemetrexed 25

26 Tecentriq in 1L non-squamous NSCLC IMpower150: A unique opportunity in key subgroups PDL-1 status (SP142 and SP263) and Teff signatures EGFR/ALK genetic alterations and liver metastases Clinically meaningful PFS benefit in ITT and key subgropus (EGFR/ALK+ and patients with liver metastases) PD(L)1 monotherapy has not shown significant benefit in 2L EGFR/ALK+ patients Tumors in patients with liver metastases are characterized by immune suppressive tumor environments, and they usually demonstrate poorer outcomes The observed efficacy in these key subgroups may be due to the addition of Avastin to Tecentriq Kowanetz M, et al., AACR 2018; ITT=intent-to-treat; WT=wild type; mpfs=median progression free survival; TC=tumor cells; IC=immune cells 26

27 Hemlibra: BTD for non-inhibitor prophylaxis HAVEN 3 and 4 submitted to WFH HAVEN 3 and 4 submitted to WFH (Glasgow, May 20-24) Hemlibra designated as Part B drug by CMS BTD=breakthrough designation; WFH=world federation of hemophilia; CMS=centers for medicare & medicaid services 27

28 Baloxavir marboxil* in Influenza A & B FDA filing for healthy adults and adolescents planned in 2018 CAP-dependent endonuclease inhibitor Phase III (CAPSTONE-1) results for acute uncomplicated influenza Small molecule inhibiting viral RNA replication via a novel and highly selective mode of action One-time dosing due to long halflife + well tolerated Significant reduction in time to alleviation of symptoms by >24 hrs vs placebo (p<0.0001) Time to cessation of viral shedding reduced by 48 hrs vs Tamiflu (p<0.0001) potentially leading to reduced transmission rates Approved in Japan in Feb 2018 Ongoing Ph III development program in populations at high risk and pediatrics Kawaguchi, et al. ESWI 2017; Portsmouth, et al. IDWeek 2017; a 95% CI of median time could not be obtained by Brookmeyer and Crowley method (1982); b Not determined; *Co-development with Shionogi; Roche holds worldwide license excluding Japan and Taiwan 28

29 Acquisition of Flatiron in Q1 Leading player driving personalized patient care in oncology Strong network in Oncology Leading EMR system and analytics solutions used by ~15% of US oncologists and covering ~15% of active patients Leading real world data base Research-quality EMR data base covers 10m patients, over 2m of them active 90% of large Pharma companies are working with Flatiron data While Flatiron will remain independent, acquisition will help to expand our existing partnership and provide required resources to accelerate key strategic projects in the field of personalized healthcare 29

30 ASCO 2018: Highlights in various cancer types* Lung Tecentriq + cb/pac +/- Avastin: Ph III OS (IMpower150) in 1L non-squamous NSCLC Tecentriq + cb + pac/nab-pac: Ph III PFS (IMpower131) in 1L squamous NSCLC Alecensa: Ph III update (ALEX) in 1L ALK+ NSCLC Hepatocellular carcinoma Tecentriq + Avastin: Ph Ib expansion (GO30140) in HCC Breast Ipatasertib: Ph II (LOTUS) in 1L TNBC Biomarker development Tecentriq: Ph II interim analysis (B-F1RST) to support blood TMB as predictive biomarker Tecentriq: Tissue TMB as predictive biomarker in NSCLC, muc and melanoma Hematology Venclexta + Rituxan: Ph III (MURANO) MRD analysis in R/R CLL Venclexta + dec/aza: Ph Ib (NCT ) in 1L AML Venclexta + car + dex: Ph II (NCT ) in R/R MM *Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change; cb=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); TMB= tumor mutational burden; aza=azacitidine; dec=decitabine; car=carfilzomib; dex=dexamethasone; Alecensa in collaboration with Chugai; Venclexta in collaboration with AbbVie 30

31 Q performance Innovation Outlook 31

32 2018: Key late-stage news flow* Compound Indication Milestone Ocrevus RMS / PPMS EU approval Perjeta + Herceptin Adjuvant HER2+ ebc EU approval Tecentriq + cb/pac +/- Avastin 1L non-sq NSCLC US/EU filing Tecentriq + Avastin 1L RCC US/EU filing Regulatory Hemlibra Hemophilia A inhibitors EU approval Hemlibra Hemophilia A non-inhibitors US/EU filing Hemlibra Every 4 weeks dosing inhibitors/non-inhibitors US/EU filing baloxavir marboxil Influenza A and B US filing Venclexta + Rituxan R/R CLL US/EU approval Tecentriq + chemo 1L lung program Ph III IMpower130/132/133 Phase III readouts Tecentriq + chemo 1L lung program Ph III IMpower131 Tecentriq + nab-pac 1L TNBC Ph III IMpassion130 Tecentriq + Cotellic 2/3L CRC Ph III IMblaze370 / COTEZO Actemra Systemic sclerosis Ph III focussced * Outcome studies are event-driven: timelines may change 32

33 Diagnostics Division Roland Diggelmann CEO Roche Diagnostics 33

34 Q1 2018: Diagnostics Division sales Good growth in all business units Change in % CHFm CHFm CHF CER Diagnostics Division 2,911 2, Centralised and Point of Care Solutions 1,716 1, Diabetes Care Molecular Diagnostics Tissue Diagnostics CER=Constant Exchange Rates Underlying growth of Molecular Diagnostics excluding sequencing business: +7% 34

35 Q1 2018: Diagnostics regional sales Growth driven by Asia Pacific and North America North America +7% 26% of divisional sales EMEA 1 +2% 42% of divisional sales Japan -8% 3% of divisional sales Latin America +1% 6% of divisional sales Asia Pacific +10% 23% of divisional sales +9% growth in E7 countries 2 1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates 35

36 Q1 2018: Diagnostics Division highlights Growth driven by Immunodiagnostics YoY CER growth Centralised and Point of Care Solutions +4% Immunodiagnostics (+5%); clinical chemistry (+3%) Diabetes Care +5% US blood glucose measurement business (+24%) Molecular Diagnostics 1 +6% Virology (+5%), HIV (+20%); HPV (+5%); cobas Liat (+262%) Tissue Diagnostics +7% EMEA North America RoW Advanced staining portfolio (+8%); primary staining (+20%) CHFbn Underlying growth of Molecular Diagnostics excluding sequencing business: +7% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 36

37 5,000 installations of cobas 8000 modular analyzer series Performing 15m tests/day +30% 4,878 5,188 No of installations 3,747 2,945 2,222 1, YTD March

38 Strong Flu season driving cobas Liat System sales Pediatric and emergency room focus segments Growing number of placements worldwide US ~1500 EU ~220 cobas Liat Analyzer cobas Liat assay tube APAC ~15 Chile ~8 Easy to use with less than one minute hands on time Lab quality performance in 20 minutes or less Menu of assays available Suitable for testing in a variety of settings CE US cobas Influenza A/B cobas Strep A cobas Influenza A/B & RSV cobas Cdiff 38

39 Launch of cobas Plasma Separation Card For testing and monitoring of HIV patients in resource limited settings No refrigeration needed for patient plasma samples during transport to the lab Only card that meets the WHO sensitivity requirement for determining HIV treatment Compatible with HIV-1 viral load testing on the cobas 6800/8800 and cobas AmpliPrep/TaqMan systems 39

40 Launch* of VENTANA DP 200 slide scanner for digital pathology Reliable, high-speed scanning of histology slides, with excellent image quality Unique no-touch slide processing reduces slide handling errors Application of the International Color Consortium profile matching what is observed under a microscope Digital Imaging and Communications in Medicine (DICOM) Standard compatible VENTANA DP 200 slide scanner Provides a foundation for a future menu of Roche image analysis algorithms *CE marked for IVD use; approved in the US for research use only 40

41 Key launches 2018 Area Product Market Central Laboratory cobas pro integrated solution Serum Work Area solution for medium throughput to lower high throughout labs CE Specialty Testing cobas m 511 World's first fully digital morphology analyzer and cell counter US Instruments/ Devices Workflow CCM connectivity to cobas c513 Connection of cobas c 513 to CCM Automation System for high volume HbA1c testing WW Tissue Dx BenchMark ULTRA Plus New and differentiated Advanced Staining System CE Digital Pathology VENTANA DP200 Reliable low-volume scanner with superior image quality CE Diabetes Care Solo Patch Pump Small and tubeless insulin delivery device operated through a remote control which includes a blood glucose meter Endocrinology IGFBP3 Completion of the existing growth hormone menu of hgh and IGF-1 CE CE Tests/ Assays Infectious Diseases Zika IgG Highly specific immunoassay for the in vitro qualitative detection of IgG antibodies to Zika virus in human serum and plasma cobas CT/NG Highest throughput CT/NG test on the market with workflow efficiency benefits US Microbiology cobas 6800/8800 MTB/MAI High volume solution for MTB/MAI testing; efficient approach to disease management (mixed testing) for infectious disease CE Virology Plasma Separation Card Card-like sample collection device; separates plasma from whole blood; for use with CAP/CTM HIV- 1 & cobas HIV-1 (6800/8800) CE Sequencing AVENIO FFPET RUO oncology kits 3 separate tissue based assay kits for solid tumors WW CE Software Decision Support NAVIFY Tumor Board v 1.x EMR integration WW 41

42 Finance Alan Hippe Chief Financial Officer 42

43 Q1 2018: Highlights Sales Strong Group sales growth, particularly in the US (+14%) and International (+6%) Strong growth in both divisions, Pharmaceuticals (+7%); Diagnostics (+5%) M&A Ignyta deal closed (USD 1.7bn) Flatiron Health deal closed (USD 1.9bn) Currency impact on sales Overall slightly negative - negative USD development only partially offset by EUR All growth rates at Constant Exchange Rates (CER) 43

44 Q1 2018: Group sales Sales increase driven by US, Diagnostics Division and International +15% -7% +5% 0% +5% +6% +5% +757 Pharma Division +7% United States Europe Intl. Japan Diagnostics Division Group Fx Group CHF 1 Absolute values and growth rates at Constant Exchange Rates (CER) ¹ average Full Year 2017 to average Q Fx 44

45 Exchange rate impact on sales growth Negative impact from USD, partially offset by EUR +1.6p +0.3p +0.1p 0.0p -0.1p -0.5p -2.8p CER sales growth YTD Mar 2018 vs. YTD Mar % +5.0% CHF sales growth YTD Mar 2018 vs. YTD Mar 2017 CER EUR Other Europe As-Pac Other JPY Lat-Am USD CHF CER = Constant Exchange Rates (avg full year 2017) 45

46 Low currency impact expected in 2018 CHF / USD Average YTD % -4% -3% -3% Assumed average YTD J F M A M J J A S O N D Assuming the 31 March 2018 exchange rates remain stable until end of 2018, 2018 impact is expected to be (%p): Monthly avg fx rates 2018 Fx rates at 31 Mar 2018 Q1 HY Sep YTD FY CHF / EUR +9% +9% +7% +6% Sales Core operating profit 0-1 Core EPS J F M A M J J A S O N D 46

47 2018 outlook raised From stable to low single digit to low single digit Group sales growth 1 Low-single digit Core EPS growth 1 Broadly in line with sales, excl. US tax reform benefit High-single digit, incl. US tax reform benefit Dividend outlook Further increase dividend in Swiss francs 1 Sales growth at Constant Exchange Rates (CER) 47

48 Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q results Diagnostics Foreign exchange rate information 48

49 Changes to the development pipeline Q update New to phase I New to phase II New to phase III New to registration 2 NMEs: RG6148 NME HER2+ BC RG6173 NME asthma 1 NME: RG6268 entrectinib NSCLC ROS1+ 2 AIs: RG7446 Tecentriq + Avastin 1L HCC RG7446 Tecentriq SCCHN adj 1 AI: RG105 MabThera/Rituxan pemphigus vulgaris 1 NME from Chugai: CHU NME - endometriosis 1 AI: RG6268 entrectinib NTRK1 pan tumor 3 AIs: RG7421 Cotellic + Tecentriq RCC, UC, H&N cancer RG7440 ipatasertib + Tecentriq + taxane - TNBC RG7601 Venclexta + Cotellic ± Tecentriq - MM Removed from phase I Removed from phase II Removed from phase III Removed from registration 1 NME: RG7945 NME - glaucoma 1 NME: RG3637 lebrikizumab ± Esbriet IPF 1 NME following EU approval: RG6013 Hemlibra hemophilia A FVIII inh 1 AI following US approval: RG3645 Lucentis 0.3mg PFS DME/DR Status as of April 26,

50 Roche Group development pipeline RG6264 Perjeta + Herceptin FDC SC HER2+ BC RG6026 CD20 TCB heme tumors RG6058 tiragolumab (TIGIT) ± T solid tumors RG AML RG6114 mpi3k alpha inh HR+ BC RG6146 BET inh combos solid + heme tumors RG HER2+ BC RG multiple myeloma RG6171 SERD (3) ER+ (HER2neg) mbc RG6180 personalized cancer vaccine ± T oncology RG6185 pan-raf inh + Cotellic solid tumors RG7155 emactuzumab + T solid tumors emactuzumab + selicrelumab solid tumors RG7159 anti-cd20 combos heme tumors RG7386 FAP-DR5 bimab solid tumors Cotellic + Zelboraf + T melanoma RG7421 Cotellic + T 2L BRAF WT mm Cotellic + T RCC, UC, H&N ca RG7440 ipatasertib + taxane + T TNBC Tecentriq solid tumors Tecentriq NMIBC RG7446 T-based Morpheus platform solid tumors T + Avastin + Cotellic 2/3L CRC T ± Avastin ± chemo HCC, GC, PaC Phase I (45 NMEs + 26 AIs) T + Cotellic solid tumors T + ipi/ifn solid tumors T + Tarceva/Alecensa NSCLC T + anti-cd20 combos heme tumors T ± lenalidomide ± daratumumab MM RG7446 T + K/HP HER2+ BC T + HMA MDS T + radium 223 mcrpc T + guadecitabine AML T + rucaparib ovarian ca T + Gazyva/tazemetostat r/r DLBCL + FL RG7461 FAP IL2v FP combos solid tumors Venclexta + Cotellic/idasanutlin AML RG7601 Venclexta ± azacitadine r/r MDS Venclexta + Cotellic ± T MM RG7741 ChK1 inh solid tumors RG7802 CEA TCB ± T solid tumors RG7813 CEA IL2v FP* + T solid tumors RG7828 CD20 TDB ± T heme tumors RG7876 selicrelumab (CD40) + T solid tumors selicrelumab + vanucizumab solid tumors RG7882 MUC16 ADC ovarian ca CHU Raf/MEK dual inh solid tumors glypican-3/cd3 bimab solid tumors RG6069 anti-fibrotic agent fibrosis RG6107 C5 inh MAb PNH RG asthma RG asthma RG inflammatory diseases RG7835 IgG-IL2 FP autoimmune diseases RG7880 IL-22Fc inflammatory diseases RG asthma RG6004 HBV LNA HBV RG6080 nacubactam bact. infections RG7854 TLR7 agonist (3) HBV RG7861 anti-s. aureus TAC infectious diseases RG7907 HBV Capsid (2) HBV RG7992 FGFR1/KLB MAb metabolic diseases RG ALS RG6029 Nav1.7 inh (2) pain RG6042 ASO Huntington s RG7816 GABA Aa5 PAM autism RG psychiatric disorders RG geographic atrophy PTH1 recep. ago hypoparathyroidism CHU - hyperphosphatemia - endometriosis New Molecular Entity (NME) CardioMetabolism RG-No Roche/Genentech *INN: cergutuzumab amunaleukin Additional Indication (AI) Neuroscience CHU Chugai managed **out-licensed to Galderma and Maruho AD Oncology Ophthalmology PRO Proximagen managed *** Ph2 pivotal Immunology Other NOV Novimmune managed T=Tecentriq Infectious Diseases RG1569 Branded as RoActemra (EU) TCB=T cell bispecific TDB=T cell dependent bispecific Status as of April 26,

51 Roche Group development pipeline Phase II (19 NMEs + 10 AIs) RG6268 entrectinib NSCLC ROS1+ entrectinib NTRK1 pan tumor RG7388 idasanutlin polycythemia vera RG7421 Cotellic + T ± taxane TNBC RG7440 ipatasertib TNBC neoadj RG7596 polatuzumab vedotin r/r DLBCL + FL Venclexta + Rituxan DLBCL RG7601 Venclexta + Rituxan r/r FL Venclexta + azacitadine 1L MDS RG7604 taselisib + letrozole (HER2-neg) BC neoadj RG7686 codrituzumab HCC RG6125 Cadherin-11 MAb RA RG6149 ST2 MAb asthma RG7159 obinutuzumab lupus RG7625 Cat-S antag autoimmune diseases RG7845 fenebrutinib (BTK inh) RA, lupus, CSU CHU nemolizumab** pruritus in dialysis patients PRO VAP-1 inh inflammatory disease NOV TLR4 MAb autoimmune diseases CHU URAT1 inh gout RG1662 basmisanil CIAS RG1678 bitopertin beta thalassemia RG6083 olesoxime SMA RG6100 Tau MAb Alzheimer s RG7314 balovaptan autism RG7916 SMN2 splicer(2)*** SMA RG7935 α-synuclein MAb Parkinson's RG3645 ranibizumab PDS wamd RG7716 VEGF-ANG2 bimab wamd, DME Status as of April 26, 2018 RG3502 Kadcyla HER2+ BC adj Kadcyla + Perjeta HER2+ BC adj RG6013 Hemlibra hemophilia A w/o FVIII inh Hemlibra Q4W hemophilia A RG7388 idasanutlin + chemo AML RG7440 ipatasertib + abiratorone 1L CRPC ipatasertib + chemo 1L TNBC/HR+ BC RG7421 Cotellic+Zelboraf+T 1L BRAFm melanoma Cotellic + T 1L BRAF WT melanoma RG7596 polatuzumab vedotin 1L DLBCL Tecentriq NSCLC adj Tecentriq MIBC adj Tecentriq Dx+ 1L sq + non-sq SCLC Tecentriq RCC adj T + nab-paclitaxel 1L non-sq NSCLC T + chemo+ Avastin 1L ovarian cancer T + chemo + Avastin 1L non-sq NSCLC T + pemetrexed 1L non-sq NSCLC T + nab-paclitaxel 1L sq NSCLC RG7446 T ± chemo SCCHN adj T + paclitaxel 1L TNBC T + nab-paclitaxel 1L TNBC T + nab-paclitaxel TNBC neoadj T + Avastin RCC T + Avastin 1L HCC T + Cotellic 3L CRC T ± chemo 1L muc T + chemo 1L extensive stage SCLC T + enzalutamide CRPC Phase III (9 NMEs + 36 AIs) RG7446/RG7853 Tecentriq or Alecensa 1L NSCLC Dx+ Venclexta + Gazyva 1L CLL RG7601 Venclexta + bortezomib MM Venclexta + azacitidine 1L AML Venclexta + LDAC 1L AML RG7604 taselisib + fulvestrant ER+(HER2-neg) mbc RG105 MabThera pemphigus vulgaris RG1569 Actemra systemic sclerosis RG3648 Xolair nasal polyps RG7413 etrolizumab ulcerative colitis etrolizumab Crohn s RG6152 baloxavir marboxil influenza RG1450 gantenerumab Alzheimer s RG6168 satralizumab NMO RG6206 anti-myostatin adnectin DMD RG7412 crenezumab Alzheimer s Registration (5 AIs) RG435 Avastin 1 ovarian FL RG1273 Perjeta + Herceptin 2 HER2+ BC adj RG7601 Venclexta + Rituxan r/r CLL RG1569 Actemra auto injector 3 RA RG105 MabThera/Rituxan pemphigus vulgaris 1 US only, 2 Approved in US, 3 Approved in EU See previous page for legend 51

52 NME submissions and their additional indications Projects currently in phase II and III New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU RG1450 gantenerumab Alzheimer s RG1662 basmisanil CIAS RG7716 VEGF/ANG2 bimab wamd/dme RG1678 bitopertin beta thalassemia RG6125 Cadherin-11 MAb RA RG6206 anti-myostatin adnectin DMD RG6083 olesoxime SMA RG6149 ST2 MAb asthma RG6168 satralizumab (SA237) neuromyelitis optica RG7916 SMN2 splicer(2) SMA RG7388 idasanutlin polycythemia vera RG6100 Tau MAb Alzheimer s RG7413 etrolizumab ulcerative colitis RG6152 baloxavir marboxil Influenza RG6268 entrectinib NSCLC ROS1+ RG7440 ipatasertib+abiratorone 1L CRPC RG7440 ipatasertib TNBC neoadj RG7314 balovaptan autism RG7413 etrolizumab Crohn s RG7596 RG7604 polatuzumab vedotin r/r DLBCL taselisib+fulvestrant PIK3CAmut ER+ (HER2-neg) mbc RG6268 RG7388 entrectinib NTRK1 pantumor idasanutlin AML RG7596 RG7440 polatuzumab vedotin r/r FL ipatasertib +chemo 1L TNBC / HR+ BC and beyond RG7596 RG7604 polatuzumab vedotin 1L DLBCL taselisib + letrozole ER+ (HER2-neg) BC neoadj RG7412 RG7935 crenezumab Alzheimer s α-synuclein MAb Parkinson s RG7625 RG7845 Cat S antag autoimmune diseases fenebrutinib autoimmune diseases Status as of April 26,

53 AI submissions for existing products; currently in phase II and III RG105 RG1569 RG1569 RG6013 RG6013 MabThera pemphigus vulgaris Actemra systemic sclerosis Actemra auto injector (US) RA/GCA Hemlibra hemophilia A FVIII non-inh Hemlibra hemophilia A, Q4W New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU RG7601 Venclexta + Rituxan (EU) r/r CLL RG7601 Venclexta + aza/ldac 1L AML RG7446 RG7446 RG7446 RG7446 Tecentriq + Cotellic 3L CRC Tecentriq+chemo+Avastin 1L non-sq NSCLC Tecentriq + nab-paclitaxel 1L sq NSCLC Tecentriq + nab-paclitaxel 1L non-sq NSCLC RG7421 RG7421 RG7446 Cotellic + Tecentriq 1L BRAF WT melanoma Cotellic + Tecentriq + Zelboraf 1L BRAFmut melanoma Tecentriq 1L non-sq + sq NSCLC (Dx+) RG3648 RG3502 Xolair nasal polyps Kadcyla HER2+ BC adj. RG3645 RG7159 RG7446/ RG7853 RG7446 ranibizumab PDS wamd obinutuzumab lupus nephritis Tecentriq or Alecensa 1L NSCLC Dx+ Tecentriq NSCLC adj RG7446 Tecentriq + pemetrexed 1L non-sq NSCLC RG7446 Tecentriq + nab-paclitaxel TNBC neoadj RG3502 Kadcyla + Perjeta HER2+ BC adj. RG7601 Venclexta + Rituxan r/r FL RG7446 Tecentriq MIBC adj RG7446 Tecentriq + chemo 1L extens. stage SCLC RG7446 Tecentriq + paclitaxel 1L TNBC RG7446 Tecentriq ± chemo 1L muc RG7601 Venclexta + Rituxan DLBCL RG7446 Tecentriq RCC adj RG7446 Tecentriq + Avastin RCC RG7601 Venclexta + Gazyva 1L CLL RG7446 Tecentriq + enzalutamide CRPC RG7601 Venclexta + aza 1L MDS RG7446 Tecentriq + Avastin 1L HCC RG7446 Tecentriq + nab-paclitaxel TNBC RG7601 Venclexta + bortezomib MM RG7446 Tecentriq+chemo+Avastin 1L ovarian cancer RG7421 Cotellic+Tecentriq±taxane TNBC RG7446 Tecentriq + chemo SCCHN adj and beyond Status as of April 26,

54 Major granted and pending approvals 2018 US EU Japan-Chugai Approved RG3645 Lucentis 0.3 mg PFS DME/DR, March 2018 RG1594 RG6013 RG1569 Ocrevus PPMS & RMS, Jan 2018 Hemlibra (emicizumab) hemophilia A FVIII inh (ped/adults), February 2018 Actemra auto injector RA, March 2018 RG6013 RG7446 Hemlibra (emicizumab) hemophilia A FVIII inh (ped + adults), March 2018 Tecentriq 2L+ NSCLC, Jan 2018 Pending Approval RG435 RG7601 Avastin Ovarian FL, Filed Aug 2017 Venclexta + Rituxan r/r CLL, Filed Dec 2017 RG1273 RG7601 Perjeta + Herceptin HER2+ BC adj, Filed Aug 2017 Venclexta + Rituxan r/r CLL, Filed Jan 2018 RG7446 Tecentriq + other anti-tumor drugs 1L NSCLC, March 2018 RG1569 Actemra auto injector RA/GCA, Filed Jan 2018 RG105 MabThera pemphigus vulgaris, Filed Feb 2018 RG105 Rituxan pemphigus vulgaris, Filed Dec 2017 New Molecular Entity (NME) CardioMetabolism Status as of April 26, 2018 Additional Indication (AI) Oncology Immunology Infectious Diseases Neuroscience Ophthalmology Other 54

55 Cancer immunotherapy pipeline overview RG6026 CD20 TCB hematopoietic tumors RG6058 tiragolumab (TIGIT) ± T solid tumors RG multiple myeloma RG6180 personalized cancer vaccine ± T oncology RG7155 emactuzumab + T solid tumors emactuzumab + selicrezumab solid tumors Cotellic + Zelboraf + T melanoma RG7421 Cotellic + T BRAF WT mm 2L Cotellic + T RCC, UC, H&N ca RG7440 ipatasertib + taxane + T TNBC Tecentriq solid tumors Tecentriq NMIBC T-based Morpheus platform pancreatic ca T + Cotellic ± Avastin 2/3L CRC T ± Avastin ± chemo HCC, GC, PaC T + Cotellic solid tumors T + ipi/ifn solid tumors RG7446 T + Tarceva/Alecensa NSCLC T + anti-cd20 multiple combos lymphoma T ± lenalidomide ± daratumumab MM T + K/HP HER2+ BC T + HMA MDS T + radium 223 mcrpc T + guadecitabine AML T + rucaparib ovarian ca T + Gazyva/tazemetostat r/r DLBCL + FL RG7461 FAP IL2v FP combos solid tumors RG7601 Venclexta + Cotellic ± T MM RG7802 CEA TCB ± T solid tumors RG7813 CEA IL2v FP* + T solid tumors RG7828 CD20 TDB ± T solid tumors RG7876 selicrelumab (CD40) + T solid tumors selicrelumab + vanucizumab solid tumors Status as of April 26, 2018 Phase I (10 NMEs + 32 AIs) AMGN** Tecentriq + talimogene laherp TNBC, CRC Checkmate** Tecentriq + CMP-001 NSCLC BLRX** Tecentriq + BL-8040 AML, solid tumors CRVS** Tecentriq + CPI-444 solid tumors EXEL** Tecentriq + cabozantinib solid tumors HALO** Tecentriq + PEGPH20 CCC, GBC INO** Tecentriq + INO5401+INO9012 bladder ca JNJ** Tecentriq ± daratumumab solid tumors KITE** Tecentriq + KTE-C19 r/r DLBCL MORPHEUS Platform - Phase Ib/II (5 AIs) RG7446 T-based Morpheus T-based Morpheus T-based Morpheus T-based Morpheus T-based Morpheus Phase II (5 AIs) pancreatic cancer gastric cancer HR+ BC NSCLC 2L TNBC RG7421 Cotellic + T ± taxane TNBC Gradalis** Tecentriq + Vigil ovarian ca GTHX** Tecentriq + trilaciclib SCLC IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma SNDX** Tecentriq + entinostat TNBC ** External collaborations: AMGN Amgen oncolytic virus; BLRX - BioLine Rx CXCR4 antag; Checkmate - TLR9 agonist; CRVS Corvus ADORA2A antag; EXEL Exelexis TKI; Gradalis EATC therapy; GTHX G1 Therapeutics CDK4/6; HALO Halozyme PEGPH20; IMDZ Immune Design CMB305; INO - Inovio T cell activating immunotherapy (INO-5401), IL-12 activator (INO-9012); JNJ Janssen CD38 MAb; KITE Kite KTE-C19; SNDX Syndax HDAC inh Phase III (22 AIs) RG7421 Cotellic+Zelboraf+T 1L BRAFm melanoma Cotellic + T 1L BRAF WT melanoma Tecentriq NSCLC adj Tecentriq MIBC adj Tecentriq Dx+ 1L sq + non-sq SCLC Tecentriq RCC adj T + nab-paclitaxel 1L non-sq NSCLC T + chemo + Avastin 1L ovarian cancer T + chemo + Avastin 1L non-sq NSCLC T + pemetrexed 1L non-sq NSCLC T + nab-paclitaxel 1L sq NSCLC RG7446 T ± chemo SCCHN adj T + paclitaxel 1L TNBC T + nab-paclitaxel 1L TNBC T + nab-paclitaxel TNBC neoadj T + Avastin RCC T + Avastin 1L HCC T + Cotellic 3L CRC T ± chemo 1L muc T + chemo 1L extensive stage SCLC T + enzalutamide CRPC RG7446/RG7853 Tecentriq or Alecensa 1L NSCLC Dx+ New Molecular Entity (NME) RG-No Roche/Genentech Additional Indication (AI) *INN: cergutuzumab amunaleukin Oncology T=Tecentriq; TCB=T cell bispecific TDB=T cell dependent bispecific 55

56 Doing now what patients need next